Pfizer Expands Anti-Infective Portfolio With $1.9 Bil. Vicuron Acquisition

Vicuron's near-term candidates include the antibiotic dalbavancin, which has a Sept 21 user fee deadline, and the antifungal anidulafungin, also pending at FDA. Pfizer's acquisition of Vicuron is expected to close in the third quarter.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet